Canada Ankylosing Spondylitis Market Size & Outlook
Canada ankylosing spondylitis market highlights
- The Canada ankylosing spondylitis market generated a revenue of USD 167.9 million in 2019 and is expected to reach USD 395.4 million by 2027.
- The Canada market is expected to grow at a CAGR of 11.3% from 2020 to 2027.
- In terms of segment, humira was the largest revenue generating drug in 2019.
- Others Drugs is the most lucrative drug segment registering the fastest growth during the forecast period.
Ankylosing spondylitis market data book summary
| Market revenue in 2019 | USD 167.9 million |
| Market revenue in 2027 | USD 395.4 million |
| Growth rate | 11.3% (CAGR from 2019 to 2027) |
| Largest segment | Humira |
| Fastest growing segment | Others Drugs |
| Historical data | 2016 - 2018 |
| Base year | 2019 |
| Forecast period | 2020 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia, Others Drugs |
| Key market players worldwide | AbbVie Inc, Amgen Inc, Pfizer Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Johnson & Johnson, Merck & Co Inc |
Other key industry trends
- In terms of revenue, Canada accounted for 4.0% of the global ankylosing spondylitis market in 2019.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2027.
- In North America, U.S. ankylosing spondylitis market is projected to lead the regional market in terms of revenue in 2027.
- Canada is the fastest growing regional market in North America and is projected to reach USD 395.4 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Ankylosing Spondylitis Market Scope
Ankylosing Spondylitis Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| UCB SA | View profile | 9083 | Allee de la Recherche, 60, Brussels, Belgium, B-1070 | https://www.ucb.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Amgen Inc | View profile | 26700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | https://www.amgen.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Canada ankylosing spondylitis market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to ankylosing spondylitis market will help companies and investors design strategic landscapes.
Humira was the largest segment with a revenue share of 24.48% in 2024. Horizon Databook has segmented the Canada ankylosing spondylitis market based on cosentyx, humira, simponi, remicade, enbrel, cimzia, others drugs covering the revenue growth of each sub-segment from 2021 to 2033.
- Canada Ankylosing Spondylitis Drug Class Outlook (Revenue, USD Million, 2021-2033)
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- TNF Inhibitors
- Humira
- Simponi
- Remicade
- Enbrel
- Cimzia
- Other TNF Inhibitors
- Other Drug Classes
- Canada Ankylosing Spondylitis Distribution Channel Outlook (Revenue, USD Million, 2021-2033)
- Hospital Pharmacy
- Retail Pharmacy
- Others
Reasons to subscribe to Canada ankylosing spondylitis market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Canada ankylosing spondylitis market databook
-
Our clientele includes a mix of ankylosing spondylitis market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada ankylosing spondylitis market, including forecasts for subscribers. This country databook contains high-level insights into Canada ankylosing spondylitis market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
